Thursday, October 29, 2009: 12:30 PM-3:00 PM
3.1
Validation of ADHD Subtypes Using Visual Attention and Comorbidity
Joung-Sook Ahn, M.D.
Wonju Collge of Medicine, Yonsei University, Gangwon-Do South Korea
Jong-soo Shin, M.D.
Yonsei University Wonju Christian Hospital, Wonju, Gangwon-do South Korea
3.2
Cognitive Remediation, Executive Function Deficit, and fMRI in Adolescents and Adults with ADHD
Michel Bader, M.D.
, Lausanne Switzerland
Nouchine Hadjikhani, M.D.
, Lausanne Switzerland
Blaise Pierrehumbert, Ph.D.
Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (SUPEA), Lausanne Switzerland
Sarah Leopizzi
Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (SUPEA), Lausanne Switzerland
Olivier Halfon, M.D.
Centre Hospitalier Universitaire Vaudois, Lausanne Switzerland
3.3
Safety and Efficacy of ABT-089, a Novel Alpha-4-Beta-2 Neuronal Nicotinic Receptor Partial Agonist, in the Treatment of Adults with ADHD
Earle Bain, M.D.
Abbott Laboratories, Abbott Park, IL
George Apostol, M.D., M.S.
Abbott Laboratories, Glenview, IL
R. Bart Sangal, M.D.
Clinical Neurophysiology Services, PC, Troy, MI
Weining Z. Robieson, Ph.D.
Abbott Laboratories, Abbott Park, IL
Walid M. Abi-Saab, M.D.
Novartis Pharmaceutical Corporation, Basel Switzerland
Mario Saltarelli, M.D., Ph.D.
Abbott Laboratories, Abbott Park, IL
3.4
Dopamine Transporter Gene Variation Modulates Activation of Striatum in Youth with ADHD
Anne-Claude Bedard, Ph.D.
Mount Sinai School of Medicine, New York, NY
Kurt P. Schulz, Ph.D.
Mount Sinai School of Medicine, New York, NY
Edwin H. Cook, Jr., M.D.
University of Illinois at Chicago, Chicago, IL
Jin Fan, Ph.D.
Mount Sinai School of Medicine, New York, NY
Suzanne M. Clerkin, Ph.D.
Mount Sinai School of Medicine, New York, NY
Iliyan Ivanov, M.D.
Mount Sinai School of Medicine, New York, NY
Jeffrey M. Halperin, Ph.D.
Queens College, City University of New York, Flushing, NY
Jeffrey H. Newcorn, M.D.
Mount Sinai School of Medicine, New York, NY
3.6
The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6-12 Years of Age with ADHD in a Double-Blind, Placebo-Controlled Trial
Ann Childress, M.D.
Center for Psychiatry and Behavioral Medicine, Las Vegas, NV
Valerie Arnold, M.D.
University of Tennessee, Memphis, TN
Ben Adeyi, M.S.
Shire Pharmaceuticals Inc., Wayne, PA
Bryan Dirks, M.D.
Shire Pharmaceuticals Inc., Wayne, PA
Thomas Babcock, D.O., Ph.D.
Shire Pharmaceuticals Inc., Wayne, PA
Brian Scheckner, PharmD
Shire Pharmaceuticals Inc., Wayne, PA
Robert Lasser, M.D.
Shire Pharmaceuticals Inc., Wayne, PA
Frank Lopez, M.D.
Children's Developmental Center, Winter Park, FL
3.7
Gender-Specific Association of the Brain-Derived Neurotrophic Factor Gene with ADHD in a Korean Population
Se-Jin Choi, M.D.
Seoul National University College of Medicine, Seoul South Korea
Hyo-Won Kim, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Soo-Churl Cho, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Boong-Nyun Kim, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Jae-Won Kim, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Jun-Won Hwang, M.D.
Seoul Metropolitan Eunpyeong Hospital, Seoul
Jung-Woo Son, M.D., Ph.D.
Chungbuk National University Hospital, Cheongju South Korea
Sun-Woo Jung, M.D.
Seoul National University Children's Hospital, Seoul South Korea
Un-Sun Chung, M.D., Ph.D.
Kyungpook National University Hospital, Daegu South Korea
Seockhoon Chung, M.D.
University of Ulsan College of Medicine, Asian Medical Center, Seoul South Korea
3.8
Effects of Guanfacine Extended Release in Children Aged 6 to 12 with Oppositional Symptoms and a Diagnosis of ADHD
Scott Kollins, Ph.D.
Duke University Medical Center, Durham, NC
Thomas Spencer, M.D.
Massachusetts General Hospital; Harvard Medical School, Boston, MA
Robert L. Findling, M.D.
University Hospitals Case Medical Center, Cleveland, OH
Floyd R. Sallee, M.D., Ph.D.
University of Cincinnati, Cincinnati, OH
Frank Lopez, M.D.
Children's Developmental Center, Winter Park, FL
Daniel Connor, M.D.
University of Connecticut Medical School, Farmington, CT
Andrew Lyne, M.S.C.
Shire Pharmaceuticals Inc., Basingstoke United Kingdom
Gerald Tremblay, M.D., J.D.
Shire Pharmaceuticals Inc., Wayne, PA
3.9
Modified Release Clonidine for the Treatment of Children and Adolescents with ADHD
Scott Kollins, Ph.D.
Duke University Medical Center, Durham, NC
Robert L. Findling, M.D.
University Hospitals Case Medical Center, Cleveland, OH
Sharon B. Wigal, Ph.D.
University of California at Irvine, Child Development Center, Irvine, CA
Matthew Brams, M.D.
Bayou City Research, Houston, TX
Scott D. Segal, M.D.
Segal Institute for Clinical Research, North Miami, FL
Moise Khayrallah, Ph.D.
Addrenex Pharmaceuticals, Inc., Durham, NC
3.12
Outcomes of Children Treated for ADHD in a Multi-Racial Clinical Population
Lim Choon Guan, M.B.B.S.
Institution of Mental Health/Woodbridge Hospital, Singapore Singapore
Alvin Liew, M.B.B.S.
Institution of Mental Health/Woodbridge Hospital, Singapore Singapore
Daniel Fung, M.B.B.S.
Child Guidance Clinic, Institute of Mental Health Singapore, Singapore Singapore
3.13
Severe Mood Dysregulation in a Group of Children and Adolescents with ADHD
Fusun Cuhadaroglu Cetin, M.D.
Hacettepe University School of Medicine Ihsan Dogramaci Children's Hospital, Ankara Turkey
Esra Çöp, M.D.
Sami Ulus Children's Hospital, Ankara Turkey
Zeynep Tüzün, Ph.D.
Hacettepe University School of Medicine Ihsan Dogramaci Children's Hospital, Ankara Turkey
3.14
Affective Symptoms in Youth with ADHD
Jenny Davidow, B.A.
Mount Sinai School of Medicine, New York, NY
Beth K. Krone, M.S.
Mount Sinai School of Medicine, New York, NY
Anne-Claude Bedard, Ph.D.
Mount Sinai School of Medicine, New York, NY
Iliyan Ivanov, M.D.
Mount Sinai School of Medicine, New York, NY
Mark A. Stein, Ph.D.
Institute for Juvenile Research, University of Illinois at Chicago, Chicago, IL
Erika Zeranski, M.S.
Mount Sinai School of Medicine, New York, NY
Jodi Uderman, B.A.
Mount Sinai School of Medicine, New York, NY
Jeffrey H. Newcorn, M.D.
Mount Sinai School of Medicine, New York, NY
3.15
Depression Predicts Later Child-Dependent Life Events in Youths with ADHD
W. Burleson Daviss, M.D.
University of Texas Health Science Center at San Antonio, San Antonio, TX
Rasim S. Diler, M.D.
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA
David Ravaee, D.O.
University of Texas Health Science Center at San Antonio, San Antonio, TX
3.16
Summer Stimulant Interruptions in Treatment-Adherent Children and Adolescents with ADHD
Steven C. Marcus, Ph.D.
University of Pennsylvania, Philadelphia, PA
Michael Durkin, M.S.
Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ
Paresh Chaudhari, PharmD
Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ
George Wan, Ph.D.
Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ
3.17
Association Between Symptoms and Subtypes of ADHD and Sleep Problems/Disorders
Susan Shur-Fen Gau, M.D., Ph.D.
National Taiwan University Hospital & College of Medicine, Taipei Taiwan
3.18
Safety and Efficacy of ABT-089, a Novel Alpha-4-Beta-2 Neuronal Nicotinic Receptor Partial Agonist, in the Treatment of Children with ADHD
Laura M. Gault, M.D., Ph.D.
Abbott Laboratories, Abbott Park, IL
George Apostol, M.D., M.S.
Abbott Laboratories, Glenview, IL
Timothy E. Wilens, M.D.
Massachusetts General Hospital, Boston, MA
Christopher J. Kratochvil, M.D.
University of Nebraska Medical Center, Omaha, NE
Weining Z. Robieson, Ph.D.
Abbott Laboratories, Abbott Park, IL
Coleen Hall, M.B.A., M.S.
Abbott Laboratories, Abbott Park, IL
Walid M. Abi-Saab, M.D.
Novartis Pharmaceutical Corporation, Basel Switzerland
Mario Saltarelli, M.D., Ph.D.
Abbott Laboratories, Abbott Park, IL
3.19
Reading Performance as a Function of Treatment with Lisdexamfetamine Dimesylate in Elementary School Children Diagnosed with ADHD
Sharon B. Wigal, Ph.D.
University of California at Irvine, Child Development Center, Irvine, CA
Stephanie Maltas, B.S.
University of California at Irvine, Irvine, CA
Audrey Kapelinski, L.C.S.W.
University of California at Irvine, Irvine, CA
Kenneth Steinhoff, M.D.
University of California at Irvine, Irvine, CA
Kimberley Lakes, Ph.D.
University of California at Irvine, Irvine, CA
Sabrina Schuck, Ph.D.
University of California at Irvine, Irvine, CA
Annamarie Stehli, M.P.H.
University of California at Irvine, Irvine, CA
3.20
Clinical Response and Symptomatic Remission in Children Treated with Lisdexamfetamine Dimesylate for ADHD
James J. McGough, M.D.
University of California at Los Angeles Semel Institute for Neuroscience & Human Behavior, Los Angeles, CA
Ben Adeyi, M.S.
Shire Pharmaceuticals Inc., Wayne, PA
Gary Chen, Ph.D.
Shire Pharmaceuticals Inc., Wayne, PA
Bryan Dirks, M.D.
Shire Pharmaceuticals Inc., Wayne, PA
Thomas Babcock, D.O., Ph.D.
Shire Pharmaceuticals Inc., Wayne, PA
Brian Scheckner, PharmD
Shire Pharmaceuticals Inc., Wayne, PA
Robert Lasser, M.D.
Shire Pharmaceuticals Inc., Wayne, PA
Robert L. Findling, M.D.
University Hospitals Case Medical Center, Cleveland, OH
3.21
Parental ADHD Knowledge, Medication, and Counseling Treatment Acceptability, and ADHD Service Use Among African American, Latino, and Caucasian Families
Judy Ho, Ph.D.
UCLA Health Services Research Center, Los Angeles, CA
Regina Bussing, M.D., M.P.H.
University of Florida, College of Medicine, Gainesville, FL
Bonnie Zima, M.D., M.P.H.
University of California at Los Angeles Health Services Research Center, Los Angeles, CA
Lingqi Tang, Ph.D.
University of California at Los Angeles Health Services Research Center, Los Angeles, CA
3.22
Enlarged Hippocampal Volume in Drug-Naïve Boys with ADHD: Preliminary Study
Minyoung Sim, M.D.
Seoul National University Children's Hospital, Seoul South Korea
Hanik K. Yoo, M.D.
Asan Medical Center, University of Ulsan College of Medicine, Seoul South Korea
Jaesuk Jung, M.D.
Seoul Child Psychiatric Clinic, Suwon South Korea
Yong Jin Park, M.D.
Family-Love Psychiatric Clinic, Seoul South Korea
3.23
Cardiovascular Outcomes in Children and Adults Treated with Lisdexamfetamine Dimesylate for ADHD
Richard H. Weisler, M.D.
Duke University Medical Center; University of North Carolina at Chapel Hill, Durham, NC
Lenard Adler, M.D.
New York University Langone School of Medicine and Psychiatry Service, New York, NY
Mohamed Hamdani, M.S.
Shire Development, Inc., Wayne, PA
Ben Adeyi, M.S.
Shire Pharmaceuticals Inc., Wayne, PA
Brian Scheckner, PharmD
Shire Pharmaceuticals Inc., Wayne, PA
Thomas Babcock, D.O., Ph.D.
Shire Pharmaceuticals Inc., Wayne, PA
Gwendolyn Niebler, D.O.
Shire Pharmaceuticals Inc., Wayne, PA
Ann Childress, M.D.
Center for Psychiatry and Behavioral Medicine, Las Vegas, NV
3.24
Twenty-Four Month Effectiveness of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years with ADHD
Floyd Sallee, M.D., Ph.D.
University of Cincinnati, Cincinnati, OH
Keith McBurnett, Ph.D.
University of California at San Francisco, San Francisco, CA
Timothy Wigal, Ph.D.
University of California at Irvine, Irvine, CA
Andrew Lyne, M.S.C.
Shire Pharmaceuticals Inc., Basingstoke United Kingdom
Sharon Youcha, M.D.
Shire Pharmaceuticals Inc., Wayne, PA
Jonathan Rubin, M.D., M.B.A.
Shire Pharmaceuticals Inc., Wayne, PA
3.25
Elevated Rates of ADHD in Mothers of Children with Comorbid ADHD and Epilepsy
Joseph Gonzalez-Heydrich, M.D.
Children's Hospital Boston, Boston, MA
Laura Luna, B.S., M.A.
Children's Hospital Boston, Boston, MA
Sneha Rao, B.A.
Children's Hospital Boston, Brighton, MA
Juliette McClendon, B.A.
Children's Hospital Boston, Boston, MA
Philip Rotella, B.S.
Children's Hospital Boston, Boston, MA
Deborah Waber, Ph.D.
Children's Hospital Boston, Boston, MA
Hesham Hamoda, M.D.
Boston Childrens Hospital, Harvard Medical School, Boston, MA
Katrina M. Boyer, Ph.D.
Children's Hospital Boston, Boston, MA
Stephen Faraone, Ph.D.
State University of New York Upstate Medical University, Syracuse, NY
Jane Whitney, B.A.
Children's Hospital Boston, Boston, MA
Danielle Guild, B.A.
Children's Hospital Boston, Boston, MA
Joseph Biederman, M.D.
Massachusetts General Hospital, Boston, MA
3.26
International Survey in Japan, Korea, and Taiwan: Difficulties and Problems Reported by the Parents of Children with ADHD
Taro Goto, M.D., Ph.D.
Eli Lilly and Company Japan, Kobe Japan
Michihiro Takahashi, M.D., Ph.D.
Eli Lilly and Company Japan, Kobe Japan
Yasuo Tanaka, M.D.
Hokkaido University Graduate School of Education, Sapporo Japan
3.27
ADHD and Sleep Problems: Results From a Community-Based Epidemiological Study
Joseph R. Holbrook, M.P.H.
University of South Carolina, Arnold School of Public Health, Columbia, SC
Steven P. Cuffe, M.D.
University of Florida College of Medicine- Jacksonville, Jacksonville Beach, FL
Matteo Bottai, Ph.D.
University of South Carolina, Arnold School of Public Health, Columbia, SC
Bo Cai, Ph.D.
University of South Carolina, Arnold School of Public Health, Columbia, SC
Lorie James, M.P.H.
University of South Carolina, Arnold School of Public Health, Columbia, SC
Robert E. McKeown, Ph.D.
University of South Carolina, Arnold School of Public Health, Columbia, SC
3.28
Subjective Sleep Quality of Adult Smokers, Former Smokers, and Non-Smokers with ADHD
Alex S. Holdaway, B.A.
Duke University Medical Center, Durham, NC
Elizabeth E. Van Voorhees, Ph.D.
Duke University Medical Center, Durham, NC
Kristina Hardy, Ph.D.
Duke University Medical Center, Durham, NC
Scott Kollins, Ph.D.
Duke University Medical Center, Durham, NC
3.29
ADHD Symptom Trajectories for Children Treated in Community-Based Pediatric Settings
Katherine E. House, B.A.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
William B. Brinkman, M.D.
Cincinnati Children's Hospital Medical Center, CIncinnati, OH
Joshua M. Langberg, Ph.D.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Jeffery N. Epstein, Ph.D.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3.30
Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Children and Adolescents (6–17 Years Old): Line-Item Analysis of the Aberrant Behavior Checklist Irritability Subscale
Michael G. Aman, Ph.D.
Ohio State University, Columbus, OH
William Kasper, PharmD
Bristol-Myers Squibb Company, Plainsboro, NJ
George Manos, Ph.D.
Bristol-Myers Squibb Company, Wallingford, CT
Raymond Mankoski, M.D., Ph.D.
Bristol-Myers Squibb Company, Plainsboro, NJ
Andrei Pikalov, M.D., Ph.D.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Suja Mathew, B.S.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Ronald Marcus, M.D.
Bristol-Myers Squibb Company, Wallingford, CT
Randall Owen, M.D.
Bristol-Myers Squibb Comopany, Wallingford, CT
3.31
The Children's Problem Behavior and Aggression Questionnaire (CPBAQ) in Bipolar I Disorder: Results From a Four-Week, Randomized, Placebo-Controlled Ziprasidone Trial
Michelle Stewart, Ph.D.
Pfizer Inc, New London, CT
Elizabeth Pappadopulos, Ph.D.
Pfizer Inc, New York, NY
Yifan Huang, DrPH
Pfizer Inc, New London, CT
Phillip Chappell, M.D., M.B.A.
Pfizer Inc, New London, CT
Mary Bachinsky, M.S.C.
Pfizer Inc, New London, CT
Mark Versavel, M.D., M.B.A., Ph.D.
Pfizer Inc, New London, CT
Sally Olderbak, M.A.
University of Arizona, Tucson, AZ
3.32
Somnolence and Sedation in Child and Adolescent Patients Treated with Aripiprazole
Kiki D. Chang, M.D.
Stanford University School of Medicine, Stanford, CA
Suja Mathew, B.S.
Otsuka America Pharmaceutical, Inc., Rockville, MD
William Carson, M.D.
Otsuka America Pharmaceutical, Inc., Princeton, NJ
Margaretta Nyilas, M.D.
Otsuka America Pharmaceutical, Inc., Princeton, NJ
Robert A. Forbes, Ph.D.
Otsuka America Pharmaceutical, Inc., Princeton, NJ
Taro Iwamoto, Ph.D.
Otsuka America Pharmaceutical, Inc., Princeton, NJ
Raymond Mankoski, M.D., Ph.D.
Bristol-Myers Squibb Company, Plainsboro, NJ
Andrei Pikalov, M.D., Ph.D.
Otsuka America Pharmaceutical, Inc., Rockville, MD
3.34
Suicidal Adolescent Inpatients at Risk for Early Readmission: The Effect of Psychotropic Medication Changes and Polypharmacy
Cynthia A. Fontanella, Ph.D.
The Ohio State University, Columbus, OH
Jeffrey Bridge, Ph.D.
The Research Institute at Nationwide Children's Hospital, Columbus, OH
Danielle Hiance, M.S.W.
The Ohio State University, Columbus, OH
John V. Campo, M.D.
Nationwide Children's Hospital; Ohio State University, Columbus, OH
3.35
A Double-Blind, Placebo Controlled Study of Risperidone for the Treatment of Anorexia Nervosa
Jennifer Hagman, M.D.
The Children's Hospital; University of Colorado Denver, Aurora, CO
Jane Gralla, Ph.D.
The Children's Hospital, Aurora, CO
Eric Sigel, M.D.
The Children's Hospital, Aurora, CO
Melinda Dodge, B.A.
University of Colorado Health Sciences Center, Aurora, CO
S.L. Ellert, M.S.
University of Colorado at Denver, Health Sciences Center, Aurora, CO
Rick M. Gardner, Ph.D.
University of Colorado at Denver, Denver, CO
Marianne Z. Wamboldt, M.D.
University of Colorado Health Sciences Center, Aurora, CO
3.36
Open-Label Treatment of Symptoms of Mania with Aripiprazole in Children
Jacqui Lingler, B.S.
University Hospitals Case Medical Center, Cleveland, Oh
Christine A. Demeter, M.A.
Case Western Reserve University, Cleveland, OH
Eric A. Youngstrom, Ph.D.
University of North Carolina at Chapel Hill, Chapel Hill, NC
Nora K. McNamara, M.D.
University Hospitals Case Medical Center, Cleveland, OH
Robert J. Stansbrey, M.D.
, Mentor, OH
Benjamin D. Otto, B.A.
Case Western Reserve University, Cleveland, Ohio
Brieana M. Rowles, M.A.
Case Western Reserve University, Cleveland, OH
Joseph R. Calabrese, M.D.
Robert L. Findling, M.D.
University Hospitals Case Medical Center, Cleveland, OH
3.37
QTc Interval Duration and Dispersion in Pediatric Patients Treated with Ziprasidone
Johnny Lops, D.O.
Zucker Hillside Hospital, Glen Oaks, NY
Peter Manu, M.D.
Zucker Hillside Hospital, Glen Oaks, NY
Anil K. Malhotra, M.D.
Zucker Hillside Hospital, Glen Oaks, NY
John Kane, M.D.
Zucker Hillside Hospital, Glen Oaks, NY
Christoph U. Correll, M.D.
The Zucker Hillside Hospital/Albert Einstein College of Medicine, Glen Oaks, NY
3.38
Effect of Cognitive Ability on Aripiprazole Treatment of Irritability Associated with Autistic Disorder
Raymond Mankoski, M.D., Ph.D.
Bristol-Myers Squibb Company, Plainsboro, NJ
George Manos, Ph.D.
Bristol-Myers Squibb Company, Wallingford, CT
Jessie Chambers, Ph.D.
, Plainsboro, NJ
Suja Mathew, B.S.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Andrei Pikalov, M.D., Ph.D.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Lisa Kamen, M.H.A.
Bristol-Myers Squibb Company, Plainsboro, NJ
Ronald Marcus, M.D.
Bristol-Myers Squibb Company, Wallingford, CT
Randall Owen, M.D.
Bristol-Myers Squibb Comopany, Wallingford, CT
3.39
Concomitant CYP2D6 Medications Increase Rate of Moderate-to-Severe Adverse Drug Reactions in Pediatric Psychiatric Patients on Risperidone
Kurt A. Myers, B.S.
University of Kentucky, Lexington, KY
Paul Glaser, M.D., Ph.D.
University of Kentucky, Lexington, KY
Kelli D. Frueh, B.S., R.N.
University of Kentucky, Lexington, KY
Margaret T. Susce, R.N.
University of Kentucky, Lexington, KY
Jose de Leon, M.D.
University of Kentucky, Lexington, KY
3.40
Treatment with Atypical Antipsychotics Increases the Risk for Metabolic Syndrome in Youth with Mental Illness
Constadina Panagiotopoulos, M.D., FRCPC
University of British Columbia, Vancouver, BC
Jana-Lea Davidson, M.D., FRCPC
University of British Columbia, Vancouver, BC
Margaret Weiss, M.D., F.R.C.P., Ph.D.
Children's and Women's Health Centre of British Columbia, Vancouver, BC
3.41
Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: Dose Response and Drug Effects
Mark A. Stein, Ph.D.
Institute for Juvenile Research, University of Illinois at Chicago, Chicago, IL
Elizabeth Charney, M.D.
, Glencoe, IL
Irwin Waldman, Ph.D.
Emory University, Atlanta, GA
Lauren Maul, B.A.
Institute for Juvenile Research, University of Illinois at Chicago, Chicago, IL
Reut Gruber, Ph.D.
McGill University, Montreal, QC
Jeffrey H. Newcorn, M.D.
Mount Sinai School of Medicine, New York, NY
3.42
Momentary Assessment of Social Context and Affect in Depressed Youth
Ashley D. Kendall, B.A.
Children's Hospital Boston, Boston, MA
Courtney Walls, B.A., M.P.H.
Children's Hospital Boston, Boston, MA
Henry A. Feldman, Ph.D.
Children's Hospital Boston, Boston, MA
William R. Beardslee, M.D.
Children's Hospital Boston, Boston, MA
Lydia A. Shrier, M.D., M.P.H.
Children's Hospital Boston, Boston, MA
3.45
Gender Differences in Depressed Adolescents with Substance Use Disorders in a Randomized Controlled Trial of Fluoxetine/Placebo and Cognitive Behavioral Therapy
Michelle Lohman, B.S., R.N.
University of Colorado at Denver, Aurora, CO
Paula Riggs, M.D.
University of Colorado at Denver, Aurora, CO
Shannon K. McWilliams
University of Colorado at Denver, Aurora, CO
Susan K. Mikulich-Gilbertson, Ph.D.
University of Colorado at Denver, Aurora, CO
Ashley Myracle, M.A.
University of Colorado at Denver, Denver, CO
3.47
Frequency and Risk Factors for Self-Injurious Behavior in Patients Seen in a Pediatric Psychiatric Emergency Room
Erin Callahan Soto, M.D.
Columbia Presbyterian Medical Center, New York, NY
Christoph U. Correll, M.D.
The Zucker Hillside Hospital/Albert Einstein College of Medicine, Glen Oaks, NY
3.48
Melatonin-Associated Galactorrhea
Tom Yee, APRN
Valley Mental Health, Draper, UT
Jeremy Kendrick, M.D.
University of Utah, Salt Lake City, UT
Susan T. Miller, APRN
Valley Mental Health, Kearns, UT
Poonam Soni, M.D.
University of Utah, Salt Lake City, UT
3.49
CDRS-R Subscale Analysis in a Randomized Placebo-Controlled Trial of Escitalopram in Depressed Adolescents
Adelaide Robb, M.D.
Children's National Medical Center, Washington, DC
Daniel Ventura, Ph.D.
Forest Research Institute, Jersey City, NJ
Anjana Bose, Ph.D.
Harborside Financial Center, Jersey City, NJ
Andrew Korotzer, Ph.D.
Stavros Tourkodimitris, Ph.D.
Forest Laboratories, Inc., Jersey City, NJ
3.50
Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder
Adelaide Robb, M.D.
Children's National Medical Center, Washington, DC
Carlos Fernandez, PharmD
Bristol-Myers Squibb Company, Plainsboro, NJ
Raymond Mankoski, M.D., Ph.D.
Bristol-Myers Squibb Company, Plainsboro, NJ
George Manos, Ph.D.
Bristol-Myers Squibb Company, Wallingford, CT
Suja Mathew, B.S.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Andrei Pikalov, M.D., Ph.D.
Otsuka America Pharmaceutical, Inc., Rockville, MD
Randall Owen, M.D.
Bristol-Myers Squibb Comopany, Wallingford, CT
Ronald Marcus, M.D.
Bristol-Myers Squibb Company, Wallingford, CT
3.51
Insomnia Medications and Outcomes: The Treatment of SSRI Resistant Depression in Adolescents (TORDIA) Study
Wael Shamseddeen, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA
Gregory Clarke, Ph.D.
Center for Health Research, Portland, OR
Lynn DeBar, M.P.H., Ph.D.
Kaiser Permanente Center for Health Research, Portland, OR
Graham J. Emslie, M.D.
University of Texas Southwestern Medical Center at Dallas, Dallas, TX
Karen Dineen Wagner, M.D., Ph.D.
University of Texas Medical Branch, Galveston, TX
Joan Asarnow, Ph.D.
University of California at Los Angeles, Los Angeles, CA
Martin B. Keller, M.D.
Alpert Medical School, Brown University, Providence, RI
Benedetto Vitiello, M.D.
National Institute of Mental Health (NIMH), Bethesda, MD
Anthony Spirito, Ph.D.
Brown University Center for Alcohol and Addiction Studies, Providence, RI
Satish Iyengar, Ph.D.
University of Pittsburgh, Pittsburgh, PA
Boris Birmaher, M.D.
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA
Neal D. Ryan, M.D.
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA
Giovanna Porta, M.S.
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA
David Brent, M.D.
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA
3.52
A 6-Month Follow-up Study of Posttraumatic Stress and Anxiety/Depressive Symptoms in Korean Children After Exposure to a Single-Incident Indirect Trauma
Eun-Jin Park, M.D.
Seoul National University Children's Hospital, Seoul South Korea
Boong-Nyun Kim, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Jae-Won Kim, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Hyo-Won Kim, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Min-Sup Shin, Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
Soo-Churl Cho, M.D., Ph.D.
Seoul National University Children's Hospital, Seoul South Korea
So-Yeon Lim, M.D.
Seoul National University Children's Hospital, Seoul South Korea
3.53
A Follow-up Study of Posttraumatic Stress and Comorbid Disorders in Greek Children and Adolescents After a Fire Disaster in August 2007
Gerasimos A. Kolaitis, M.D.
, Athens Greece
Chara Tzavara, M.S.C.
Centre for Health Services Research, Athens Greece
Vasiliki Moulla, Ph.D.
Vasiliki Ntre
Helen Sotiropoulou
Krystalia Paflia
Konstantina Argyrou
Katerina Kotsirilou
Vasiliki N. Leventakou, M.Sc.
Professor in Statistics at T.E.I of the Ionian Islands, Argostoli, Kephalonia Greece
Charisios Asimopoulos, Ph.D.
John Tsiantis, M.D.
Prof. of Child Psychiatry, MD, DPM, FRCpsych, Holargos Greece
Vlasis Tomaras, M.D.
Head, Athens Greece
3.54
Psychosocial Outcome of Two Psychotherapies for Childhood/Adolescence Depression
Gerasimos A. Kolaitis, M.D.
, Athens Greece
Vlasis Tomaras, M.D.
Head, Athens Greece
Judith Trowell, F.R.C.Psych.
Tavistock Clinic, London United Kingdom
Fredrik Almqvist, M.D.
Stylianos Christogiorgos, M.D.
Lecturer, Athens Greece
John Tsiantis, M.D.
Prof. of Child Psychiatry, MD, DPM, FRCpsych, Holargos Greece
3.55
Exercise for Adolescents with Depressive Disorders: A Feasibility Study
Richard Dopp, M.D.
University of Michigan, Ann Arbor, MI
Ann J. Mooney, M.S.W.
University of Michigan, Ann Arbor, MI
Lauren Buck, B.S.
University of Michigan, Ann Arbor, MI
Cheryl King, Ph.D.
University of Michigan, Ann Arbor, MI
Roseanne Armitage, Ph.D.
University of Michigan, Ann Arbor, MI
3.56
The Rapid Pediatric Psychiatric Consultation Project: Another Model of Child/Adolescent Psychiatry-Primary Care Provider Collaboration
Michael S. Adragna, M.D.
University at Buffalo School of Medicine, Buffalo, NY
David L. Kaye, M.D.
University at Buffalo School of Medicine, Buffalo, NY
Kenneth E. Leonard, Ph.D.
Universty at Buffalo School of Medicine, Buffalo, NY
Steven L. Dubovsky, M.D.
University at Buffalo School of Medicine, Buffalo, NY
3.57
The Role of Tai Chi Chuan in Improving Quality of Life and Reducing Anxiety and Depression: A Meta-Analysis
Peng Pang, M.D., Sc.M.
Maimonides Medical Center, Brooklyn, NY
Daquan Xu, M.P.H.
St. Luke's-Roosevelt Hospital Center, Manhattan, NY
Andrew Kolodny, M.D.
Maimonides Medical Center, Brooklyn, NY
